DRUG · Mapped RxNorm record
Eribulin Mesylate
Normalized identity: eribulin mesylateView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
NCT02037529
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
OTHER · Unmapped registry intervention
Laboratory Biomarker Analysis
Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Paclitaxel
Normalized identity: paclitaxelView linked drug · Find medicine records ·
Find other trials using this name
OTHER · Unmapped registry intervention
Quality-of-Life Assessment
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedEribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
Design: INTERVENTIONAL · Status: SUSPENDED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
HER2/Neu Negativeunresolved
Stage IIIC Breast Cancer AJCC v7unresolved
Stage IV Breast Cancer AJCC v6 and v7unresolved
Interventions
Eribulin MesylateDRUG · verified · RxNorm: eribulin mesylate
PaclitaxelDRUG · verified · RxNorm: paclitaxel
Sponsors & collaborators
Academic and Community Cancer Research Unitedlead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
ChicagoIllinois, United States2St LouisMissouri, United States2OmahaNebraska, United States2PortlandOregon, United States1Washington D.C.District of Columbia, United States1JacksonvilleFlorida, United States1RochesterMinnesota, United States1Chapel HillNorth Carolina, United States1Winston-SalemNorth Carolina, United States1New OrleansLouisiana, United States1ProvidenceRhode Island, United States1ScottsdaleArizona, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02037529 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.